NEW YORK, Feb 15 - Aurora Biosciences said Thursday its fourth-quarter revenue slipped 17 percent to $16.5 million, compared with $19.9 million in the year ago period. 

The San Diego-based company did not offer a reason why its revenues dropped but noted that it generated revenues from such deals as an exclusive collaboration with Senomyx to develop consumer products that enhance taste and olfaction, a licensing agreement with Deltagen, and an ion channel technology agreement with GlaxoSmithKline.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.